BioMarin Pharmaceutical Inc (BMRN) Social Stream

Featured Post From StockTwits About BMRN

$BMRN
Rare-disease biotech BioMarin Pharmaceutical (BMRN) was up sharply in premarket trading Thursday on a report that Swiss drug giant Roche (RHHBY) is thinking of making a buyout offer.

Sanofi SA (NASDAQ:SNY) has made it clear it wants to get into the rapidly growing gene therapy market, and an acquisition may be the fastest route. Rumor has it that the French pharmaceutical giant has its eyes on San Rafael, California-based Biomarin Pharmaceutical Inc. (NASDAQ:BMRN).

In 2013, there were reports that Roche was eyeing BioMarin for a possible acquisition. Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share.

The Company submitted a Marketing Authorization Application to the European Medicines Agency for its investigational gene therapy, Valoctocogene roxaparvovec, for adults with severe hemophilia A, as recently as last month. This submission marks the first marketing application submission for a gene….